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a  b  s  t  r  a  c  t
There  is increasing  interest  in  the  nature  of  the  emotion  recognition  deﬁcit  in  Huntington’s  disease  (HD).
There  are  conﬂicting  reports  of disproportionate  impairments  for some  emotions  in  some  modalities  in
HD.
A  systematic  review  and  narrative  synthesis  was  conducted  for studies  investigating  emotion  recogni-
tion  in  HD.  Embase,  MEDLINE,  PsychINFO  and  Pubmed  were  searched  from  1993 to 2010,  and  citations
and  reference  lists  were  searched.  1724  citations  were  identiﬁed.
Sixteen  studies  were  included.  In  manifest  HD  evidence  of  impaired  recognition  of  facial  expressions
of  anger  was  found  consistently,  although  recognition  of  all negative  emotions  (facial  and  vocal)  tendedeurodegenerative disorders to  be  impaired.  In premanifest  HD  impairments  were  inconsistent,  but  are  seen  in all  facial  expressions
of  negative  emotion.  Inconsistency  may  represent  the variability  inherent  in  HD  although  may  also  be
due  to between-study  differences  in methodology.
Current  evidence  supports  the  conclusion  that  recognition  of all negative  emotions  tends  to  be impaired
in  HD, particularly  in  the  facial domain.  Future  work  should  focus  on  using  more  ecologically-valid  tests,
and testing  inter-modality  differences.
©  2011  Elsevier  Ltd. Open access under CC BY-NC-ND license.ontents
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2.1.1. Types of studies. Introduction
Huntington’s disease (HD) is an autosomal dominant neu-
odegenerative disorder caused by an expanded CAG repeat on
hromosome 4. It is classically characterised by involuntary move-
ents and cognitive and psychiatric deﬁcits, with the onset of
otor signs usually occurring in mid-adulthood. There is, how-
ver, often evidence for subtle cognitive and behavioural deﬁcits
head of these motor features (Lawrence et al., 1998; Snowden
t al., 2002).
The ability to recognise emotions in others is a key social skill,
nd much work has focused on studying the expression and recog-
ition of canonical emotions (happiness, sadness, fear, surprise,
nger and disgust) which appear to be cross-cultural, and which it is
rgued have a biological basis (Ekman, 1992, 1993). More recently,
ttempts have been made to elucidate the neural substrates of emo-
ion recognition, with lesion studies and functional brain imaging
roviding new insights into the pathways underlying this skill (e.g.,
alder et al., 2004; Phillips et al., 1998; Scott et al., 1997); for a
eview see Adolphs (2002).
Over the last two decades there has been increasing interest
n emotion recognition deﬁcits in people with HD, and this inter-
st is justiﬁed on both clinical and neurobiological grounds. HD
s relatively common (Harper, 2002; Novak and Tabrizi, 2010)
nd has the potential for presymptomatic diagnosis (and there-
ore early intervention with disease-modifying therapies). These
actors lend particular urgency to the search for biomarkers of
rain dysfunction in HD, and emotion recognition is a promising
andidate (Paulsen et al., 2006; Stout et al., 2011; Tabrizi et al.,
009). In addition, HD has contributed to the literature on mod-
ls of emotion recognition, as associations are made between the
ehavioural deﬁcits seen in the disease, and the affected brain
egions.
An initial ﬁnding of disproportionately impaired recognition
f facial expressions of disgust was found in people with early
ymptoms of the disease (Sprengelmeyer et al., 1996). This was
ollowed by suggestions that facial disgust recognition might also
e affected in premanifest gene carriers (Gray et al., 1997), and that
ecognition of disgust in other modalities, such as voices, taste and
dours (Hayes et al., 2007; Mitchell et al., 2005), was also impaired.
owever other work has failed to replicate the disproportionateimpairment in disgust recognition, instead suggesting that recog-
nition of all negative emotions is broadly affected in HD (Henley
et al., 2008; Johnson et al., 2007; Milders et al., 2003). The aim
of this review was  therefore to disambiguate the pattern of emo-
tion recognition deﬁcits in HD through a systematic appraisal of
previous reports.
This review is warranted to better understand the nature
and progression of cognitive impairment in HD, and how it
might impact on people with HD and their carers. A better
conceptualisation of the emotion recognition deﬁcits in HD is
important to improve understanding of the social interaction
problems that occur in the disease. From this, more reﬁned strate-
gies for managing these problems might be developed. More
fundamentally, the emotion processing deﬁcit in HD and its
brain mechanism may  hold important clues to the pathophysi-
ology of the disease. In particular, a selective deﬁcit of emotion
comprehension would (if substantiated) potentially predict a rela-
tively speciﬁc pathophysiological and anatomical substrate which
could in turn targeted as a biomarker of disease modiﬁcation
in future therapeutic trials (Henley et al., 2005; Tabrizi et al.,
2009).
The purpose of this review was  to appraise systematically the
reported impairments in emotion recognition in HD. Such a review
is warranted in order to assess the nature of the deﬁcits reported,
and to investigate whether differences in ﬁndings can be explained
by disease-related factors, such as stage or CAG repeat length. The
review aims to ask what conclusions can be drawn from the cur-
rent literature about which emotions people with HD struggle to
recognise, and in which modalities, as well as to identify areas for
future research.
2. Methods
2.1. Criteria for considering studies for this reviewIn order to be eligible for inclusion in the review studies had
to compare emotion recognition in a group of participants with
Huntington’s disease with a control group (i.e., quasi-experimental
design). Emotion recognition was  deﬁned as any task in which
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timuli conveying emotional information were presented, and for
hich participants were asked to state or choose which emo-
ion they thought was represented by the stimuli. The stimulus
ould be of any modality (e.g. visual, vocal) and of any form (e.g.
tatic faces, videos). Any target emotions were considered. Stud-
es in which participants were asked to match emotions within a
odality were excluded (e.g. selecting a happy face in response
o a happy face stimulus); success on this task might be achieved
sing perceptual features alone. Studies in which participants were
sked to match emotions across a modality (e.g. selecting an angry
ace in response to an angry voice) were included as this cannot
e solved purely on the basis of the perceptual features of the
timuli.
Studies looking exclusively at “mood” or emotion production, or
emantic knowledge (e.g. about situations that might be expected
o induce emotions) were excluded. Editorials, reviews, commen-
aries, letters or other articles that contained no original data were
xcluded.
.1.2. Types of participants
The patient group had to consist of participants carrying
he gene coding for Huntington’s disease (Huntington’s Disease
ollaborative Research Group, 1993), conﬁrmed by genetic anal-
sis. This excluded any studies done before genetic testing
as available, but ensured that ﬁndings were speciﬁc to this
opulation.
Studies of both manifest (showing hard motor signs of HD) and
remanifest (not yet showing hard motor signs of HD) participants
ere included. Manifest HD is conventionally deﬁned as the point
t which gene carriers develop hard motor signs. Clinically, this
an be a useful way in which to deﬁne disease onset, although
n practice more subtle motor, cognitive and behavioural deﬁcits
re usually present many years before this point (Huntington
tudy Group, 1996; Paulsen et al., 2008). The control group had
o be neurologically normal participants. Studies of any partic-
pants aged 18 or over were included. Participants with onset
rior to this age are likely to have very high CAG repeat lengths
nd a rapidly progressing disease process as well as immature
motion processing mechanisms, which may  be qualitatively dis-
imilar to those in adults (Gao and Maurer, 2010; Kremer, 2002,
p. 43–44).
.1.3. Types of measures
Studies must have reported a quantitative measure of emotion
ecognition.
.2. Search methods for identiﬁcation of studies
.2.1. Electronic searches
Searches were run in the following databases: Embase
1993–July 2010), MEDLINE (1993–July 2010), PsychINFO
1993–July 2010) and PubMed (1993–July 2010).
Searches were limited from 1993 to the present day, as studies
arried out prior to this would necessarily have included partici-
ants without genetically-conﬁrmed HD.
The search used keywords “(Huntington* AND (emotion* OR
ogniti* OR neuropsycho*)) NOT (mouse OR rat OR mice)”. Using
vid the search was run on Embase, MEDLINE and PsychINFO
imultaneously and results were then deduplicated (a function
ithin Ovid).
Only peer-reviewed published articles were accepted for inclu-
ion in the review. Attempts were made to contact corresponding
uthors of all articles included in the review, either to ask for access
o more demographic or experimental data, or to check queries
bout the study.havioral Reviews 36 (2012) 237–253 239
2.2.2. Searching other resources
For each study included in the review, manual searches of refer-
ence lists were conducted and a citation search was  also conducted
to identify further potential studies.
2.3. Data collection and analysis
2.3.1. Selection of studies
The initial searches identiﬁed 1724 citations (after de-
duplication). The title and abstract of each citation were examined
independently by both SMDH and MJUN against the pre-speciﬁed
inclusion and exclusion criteria listed above.
104 citations could not be excluded on the basis of the title
and abstract alone (a proportion of these did not have an abstract
available). The full text of these citations was  obtained by SMDH
to assess whether they fully met  inclusion criteria. One additional
citation was  identiﬁed from the reference list and citation search.
2.3.2. Data extraction and management
Data were extracted to a standardised data collection form. This
covered demographic information, details of emotion recognition
tests, any background tests, results, and technical assessment.
2.3.3. Technical assessment
Study structure and technical characteristics were assessed
according to a number of criteria: sample size and power analy-
sis; the nature of the control group; reporting of demographic data,
the nature of stimuli, stimulus presentation and response options;
ways in which potential confounding variables were measured
and addressed; appropriate statistics; and reporting of quantita-
tive outcome data. Demographic data considered necessary in order
to be able to compare groups adequately between studies were:
age, gender, some measure of estimated IQ or educational level,
and additionally in the gene-positive group, CAG repeat length,
and some estimate of disease course e.g. disease duration, UHDRS
motor score or an estimate of time to motor onset in premanifest
subjects (e.g., Langbehn et al., 2004). (Note that these demographic
data were considered desirable in order to assess studies fully, but
these were not criteria for inclusion in the review overall.)
2.3.4. Data synthesis
Given that the data reviewed here were quantitative a meta-
analytic approach was  considered. Ultimately, however, a narrative
synthesis was undertaken for two reasons. Firstly, although
attempts were made to contact representatives of all the studies
included in the review, some authors could not be contacted and
this meant that quantitative results were not available for all stud-
ies. Secondly, the ways in which the HD cohorts varied between
studies were not always clear (e.g. measures such as IQ, CAG repeat
length, disease severity and duration were not always reported).
This meant that it would not be possible to determine the extent
to which differences in effect size were attributable to differences
in these factors between the cohorts studied.
3. Results
3.1. Description of studies
3.1.1. Results of the search
Sixteen reports met  full inclusion criteria. Appendix A sum-
marises reasons for which 89 studies that met initial inclusion
criteria were excluded after the full text was  examined. Of the six-
teen studies included, one or more individual experiments from
ﬁve of them were subsequently excluded for not meeting criteria
(see Appendix B).
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.1.2. Included studies
See Table 1
for characteristics of included studies.
.1.2.1. Studies of facial emotion recognition. The majority of stud-
es (14/16) included at least one test of facial emotion recognition
exceptions were Hayes et al. (2007) and Mitchell et al. (2005)).
he two most commonly used face stimulus sets were 60 (or 24)
tatic black and white images from the Ekman and Friesen battery
Ekman and Friesen, 1976), 10 (or four) each for happiness, sadness,
urprise, disgust, anger and fear, henceforth “Ekman Faces”; and
he set of 30 face images1 morphing between these six canonical
motions from the FEEST (Young et al., 2002). In this latter test, the
Emotion hexagon”, presentation of the 30 face stimuli is repeated
ver six blocks, with results from the ﬁrst block subsequently dis-
arded as practice trials. Three studies also included neutral face
timuli in at least one test (Johnson et al., 2007; Snowden et al.,
008; Tabrizi et al., 2009).
Two studies used the same brief (24-stimulus) version of Ekman
aces (Gray et al., 1997; Henley et al., 2008). Some researchers opted
o replace or supplement these tests with their own  stimuli in a
imilar format (e.g., Aviezer et al., 2009; Snowden et al., 2008). One
tudy used colour video clips made by morphing between neutral
nd emotional still photographs (Montagne et al., 2006).
One study also included a test of emotion recognition from eye
egions only (Snowden et al., 2008).
.1.2.2. Studies of auditory emotion recognition. Five studies
ncluded tests of emotion recognition in the auditory modal-
ty, testing either short non-verbal vocal sounds (e.g. laughter,
rowls) or prosody of spoken phrases constructed from non-words.
hree of these studies (Calder et al., 2010; Snowden et al., 2008;
prengelmeyer et al., 2006) used stimuli taken from the same
et of non-verbal vocal sounds (Scott et al., 1997). One study
sed their own non-verbal stimuli (Hayes et al., 2007), and two
tudies used the same “nonsense” word prosody recognition task
Sprengelmeyer et al., 1996, 2006).
.1.2.3. Studies of emotion recognition in other modalities. One study
ncluded a test of emotion recognition of static black and white
ictures portraying body language (Aviezer et al., 2009) and one,
ooking speciﬁcally at disgust recognition, tested recognition of
leasant and disgusting tastes and odours (Mitchell et al., 2005).
.1.2.4. Response options. All the studies, with the exception of
itchell et al. (2005) (investigating taste and odour perception)
sed a forced choice response paradigm, in which participants were
iven a limited set of written verbal emotion terms and asked to
ick the one that best described the stimulus.
.1.2.5. Study populations. Eight studies included a sample of pre-
anifest HD gene carriers, and 10 included a sample of people with
anifest HD (i.e., unequivocal motor signs). One study included
oth premanifest and manifest participants in the patient group
Aviezer et al., 2009).
Study populations were drawn from a range of countries, includ-
ng the United Kingdom (7), Australia (4), Germany (3), Canada (3),
he Netherlands (2), France (1) and the United States (1). Ethnicities
f participants in each country were not reported in any study. Cul-
urally, this is a relatively restricted sample, based almost entirely
n Western/European (the majority English-speaking) countries.
1 These images were based on the face known as ‘JJ’ from the Ekman and Friesen
et.havioral Reviews 36 (2012) 237–253
3.2. Assessment of methodological factors
Study methodology was  assessed in four distinct categories:
choice of control group; reporting of key demographic data and
results; stimulus type, presentation and response options; and
reporting of statistical analysis, including discussion of power,
potential confounding variables and the issue of multiple compar-
isons (Table 2).
3.2.1. Reporting of key demographic data and results
Huntington’s disease is highly heterogeneous, and clinical pre-
sentation is known to depend on age and CAG repeat length (and
their interaction); these explain some of the variance in age of
motor onset (see e.g., Mahant et al., 2003; Rosenblatt et al., 2006).
It is therefore important to be able to rule out differences in the
clinical characteristics of cohorts as a potential cause of differences
between study ﬁndings. In addition, factors such as age, education
and intelligence, and possibly gender, may  affect performance on
cognitive tasks in both HD and control groups. The impact of these
factors both within studies (between patient and control groups)
and between studies needs to be taken into account when assessing
differences in outcome. Consequently it is important for studies to
report summary data for each of these variables, so that the effects
(if any) of these potential confounders can be judged.
Four studies were considered to have reported adequate demo-
graphic data: age, gender, an index of intellectual ability, CAG
repeat length, and an index of disease severity (Henley et al., 2008;
Hennenlotter et al., 2004; Sprengelmeyer et al., 1996, 2006). Most
others reported most of the above variables but many did not
have CAG repeat data available; in these cases although partici-
pants had undergone genetic testing for conﬁrmation of diagnosis,
researchers had not always requested (or been granted access to)
the exact CAG data. Some lacked an estimate of intelligence or edu-
cational level, although some authors were able to provide the extra
data on request.
Also of note is the fact that studies varied in their deﬁnition of
pathological CAG repeat length. Typically alleles of up to 35 repeats
are considered normal, whilst alleles with 40 or more repeats are
fully penetrant and the carrier is likely to show signs of HD within
a normal lifespan. The intermediate repeat numbers (36–39) are
not fully penetrant but there have been reports of 36 CAG repeats
leading to the disease, and of people living into their 90s with 39
CAG repeats and no signs of HD (Rubinsztein et al., 1996). Whilst the
majority of studies tend to include participants with a CAG repeat
length of 40 or above, at least two  included participants with CAG
repeat lengths between 36 and 39 (Aviezer et al., 2009; Tabrizi et al.,
2009), and not all report their criteria. This raises the possibility that
some participants may  not be representative of the more general
HD population.
The majority of studies reported their ﬁndings in full (i.e., gave
quantitative measures of central tendency and spread in each of the
groups tested). A number of authors made their raw data available
on request if they were not available in the published paper. Some
authors preferred to report composite scores (Sprengelmeyer et al.,
2006; Tabrizi et al., 2009), and were able to justify this, although this
makes it difﬁcult to draw direct comparisons between individual
tests.
3.2.2. Choice of control group
Control groups were of three different kinds. Ten studies used
healthy volunteers as controls; ﬁve used gene-negative controls
from an HD environment (either people who had been at risk and
tested negative for the HD gene, or partners of gene-positive par-
ticipants); and one study used at-risk gene-negative controls who
were unaware of their negative gene status when they completed
the study tests.
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Table  1
Characteristics of included studies.
Study Demographic data Stimuli & response options
Control HD (premanifest & mild)
Aviezer et al. (2009) Expt. 1a N
Age
27
49.2 (10.0)
21
48.3 (10.1)
(1) 6 b&w pictures of body language, shown 3
times on computer; 6AFC, no time limit
Gender (%F)
CAG
56% 57%
42.85 (3.69)
(2) 40 Ekman faces, shown once on computer;
6AFC, no time limit
Estimated IQ – –
UHDRS Motor 8.26 (8.02)
Country Canada
Control Manifest HD (1) 60 Ekman faces, shown on computer for up
to 3 s; 6AFC, no time limitCalder et al.  (2010) Study 1b N Varies from 20 to 52 21 (20 for morphs)
Age “Matched” 50.43 (8.7) (2) 30 b&w morphs “Emotion Hexagon”; 5
blocks of 30 (plus practice block), each morph
shown on computer for 5 s; 6AFC, no time limit
(3) 60 non-verbal vocal sounds; 6AFC, no time
limit
Gender (%F)
CAG
Varies 43%
Genetically conﬁrmed in
most participants
Estimated IQ
UHDRS Motor
“Matched” 107.38 (8.40)
30.45 (13.10)
Country United Kingdom
Control Premanifest HD
Gray et al. (1997) N 23 17 (2 early manifest) (1) 24 Ekman faces, shown on card after 6
practice items; 6AFC, no time limitAge  38.26 (11.82) 38.53 (11.24)
Gender (%F) – –
CAG –
Estimated IQ – –
UHDRS Motor –
Country United Kingdom
Control Manifest HD
Hayes et al. (2007) N 14 14 (1) 40 non-verbal vocal sounds; 4AFC, no time limit
Age  51.3 (9.25) 54.6 (11.16)
Gender (%F) 43% 43%
CAG –
Years in
education
11.8 (2.04) 11.8 (2.12)
Disease
duration
6.7 (5.21)
Country Australia
Control Manifest HD
Hayes et al. (2009) N 14 14 (1) Emotion Hexagon (see Calder et al. entry,
above)Age  51.8 (8.37) 54.6 (11.17)
Gender (%F) 50% 43% (2) 35 b&w morphs based on Ekman faces, at
different intensities ranging from 0 to 150%, 5
blocks of 35 (plus 5 practice stimuli), each
morph shown on computer; 6AFC
CAG –
Years in
education
11.8 (1.81) 11.8 (2.12)
Disease
duration
6.7 (5.21)
Country Australia
Control Premanifest Manifest
Henley et al. (2008) N 20 21 40 (1) 24 Ekman faces, shown on card after 6
practice items; 6AFC, no time limitAge  44.9 (10.5) 37.2 (7.9) 48.5 (9.6)
Gender (%F) 65% 52% 50%
CAG 42.2 (1.8) 43.7 (2.4)
Estimated IQ 106.2 (11.6) 103.2 (9.3) 105.3 (13.0)
UHDRS Motor 1.1 (0.9) 3.6 (4.0) 28.9 (12.6)
Country United Kingdom
Control Premanifest HD
Hennenlotter et al.  (2004) N 9 9
Age “Matched” 37.4 (5.4) (1) Emotion Hexagon (see above)
Gender (%F) 44% 44%
CAG 43.7 (1.7)
Estimated IQ “Matched” 112.9 (11.1)
UHDRS Motor
Country Germany
Control Premanifest HD
Johnson et al. (2007) N 57 464 (1) 70 Ekman faces, shown on computer touch
screen for up to 4 s after 7 practice trials using
verbal labels instead of faces; 7AFC, up to 8 s to
respond using touch screen
Age, yr 43.01 (10.13) 41.43 (9.63)
Gender (%F) 61% 63%
CAG <30 >39
Years in
education
15.11 (2.29) 14.48 (2.59)
UHDRS Motor
Country United States, Canada,
Australia
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Table  1 (Continued)
Study Demographic data Stimuli & response options
Control Premanifest HD
Kipps et al. (2007) N 13 17 (1) Emotion Hexagon (see above)
Age,  yr 42.0 (11.4) 43.8 (10.0)
Gender (%F) 31% 47%
CAG 20 (3.3) 41 (2.8)
Estimated IQ – –
UHDRS Motor 3.6 (1.8) 6.4 (3.9)
Country Australia
Control Premanifest Manifest
Milders et al. (2003) N 20 20 20 (1) 60 Ekman faces, shown on card; 6AFC, no
time limitAge,  yr 47.9 (9.3) 38.4 (9.5) 47.6 (8.45)
Gender (%F) 40% 65% 40%
CAG – –
Estimated IQ 109.0 (6.0) 110.1 (6.1) 105.8 (7.41)
Disease
duration
6.5 (3.2)
Country United Kingdom
Control Manifest HD
Mitchell et al. (2005)c N
Age, yr
Gender (%F)
CAG
8 (6 for odours)
49.25 (4.86)
50%
8 (6 for odours)
53.25 (7.25)
50%
–
(1) 5 disgusting & 5 pleasant odours, presented
once for up to 5 seconds; rate odour on 10 cm
anchored line scale from very pleasant to very
disgusting
Estimated IQ – – (2) 6 everyday foods, presented individually
and then in 4 appropriate & 4 inappropriate
pairings; rate taste as for expt. 1 above
UHDRS Motor –
Country United Kingdom
Control Manifest HD
Montagne et al. (2006) N 30 7 (1) colour videos (4 sets of 9 different
intensities for each of 6 emotions), made by
morphing stills from actors, presented in 9
blocks of increasing intensity (20–100%); 6AFC,
no time limit
Age,  yr 39.0 (11.1) 46.4 (11.2)
Gender (%F) 53% 29%
CAG –
Estimated IQ – –
UHDRS Motor 17.1 (6.2)
Country The Netherlands
Control Manifest HD
Snowden et al. (2008)d N 12 10 (1) 60 Ekman faces; 6AFC, no time limit
Age, yr 57 (9) 47 (9) (2) 60 Ekman faces; 2AFC, no time limit
Gender (%F) 33% 50% (3) 120 non-verbal vocal sounds (20 for each of
6  emotions); 6AFC, no time limitCAG –
Estimated IQ 108.0 (6.7) 103.6 (10.7) (4) 35 b&w faces, “Manchester” set (5 for each of 7
emotions plus 5 practice items); 7AFC, no time
limit
UHDRS Motor
Country
United Kingdom 20.6 (8.2) (5) 35 b&w eye regions, “Manchester” set (as (4));
7AFC, no time limit
Control Manifest HD
Sprengelmeyer et al.  (1996) N 17 13 (11 for expts 2 & 3) (1) Emotion Hexagon (see above)
Age,  yr 50.7 (14.3) 45.0 (7.6) (2) 60 Ekman faces, shown on computer for up
to 3 s; 6AFC, no time limitGender (%F) 47% 54%
CAG 45.2 (4.9) (N = 11) (3) 60 “nonsense” sentences spoken with
emotional prosody; 6AFC, no time limitEstimated IQ 107.5 (10.0) 105.6 (10.7)
Disease
duration
6.6 (2.5)
Country Germany
Control Premanifest HD
Sprengelmeyer et al.  (2006) N 8 (6)e 14 (12)e (1) 60 Ekman faces, shown on computer for up
to 3 s; 6AFC, no time limitAge,  yr 38.3 (14.5) 31.0 (8.5)
Gender (%F) 75% 64% (2) Emotion Hexagon (see above)
CAG  20.4 (3.8) 45.1 (4.0) (3) 60 “nonsense” sentences spoken with
emotional prosody; 6AFC, no time limit
(4) 60 non-verbal vocal sounds; 6AFC, no time
limit
Estimated IQ
UHDRS Motor
108.8 (9.7) 113.2 (8.1)
Country Germany
S.M.D. Henley et al. / Neuroscience and Biobehavioral Reviews 36 (2012) 237–253 243
Table  1 (Continued)
Study Demographic data Stimuli & response options
Control Premanifest Manifest
Tabrizi et al. (2009)f N 123 120 123 (1) 70 Ekman faces, shown on computer touch
screen for up to 4 s after 7 practice trials using
verbal labels instead of faces; 7AFC, up to 8 s to
respond using touch screen
Age,  yr 46.1 (10.2) 40.8 (8.9) 48.8 (9.9)
Gender (%F) 55% 55% 54%
CAG 43.1 (2.4) 43.7 (3.0)
Years in
educationg
4.0 (1.3) 3.9 (1.2) 3.6 (1.3)
UHDRS Motor 2.5 (1.6) 23.7 (10.8)
Country Canada, France, The Netherlands, United Kingdom
Note: “Ekman faces” are always black & white (see text) A hyphen denotes data not reported; an empty cell denotes variable not applicable; AFC = Alternative Forced Choice
Attempts were made to contact representatives of all studies included in the review to resolve queries; responses were received from all authors other than Drs Hayes,
Hennenlotter and Sprengelmeyer.
a CAG and UHDRS motor data provided by Dr Hillel Aviezer (personal communication).
b Discrepant age data and CAG conﬁrmation provided by Prof Andy Calder (personal communication).
c Age and gender data provided by Dr Ian Mitchell (personal communication).
d IQ data provided by Dr Julie Snowden and Dr Jennifer Thompson (personal communication).
e Figures in brackets denote N at timepoints 2 and 3; data are given for all subjects at timepoint 1.
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with emotion recognition scores (Snowden et al., 2008). The others
did not take poor Benton performance into account in the emotionf CAG repeat length and UHDRS motor score provided by Prof Sarah Tabrizi and t
g UNESCO International Standard Classiﬁcation of Education: Level 3 qualiﬁcatio
K).
The rationale for using gene-negative or partner controls is that
hese people live in a similar social and emotional environment to
eople with HD; interacting with family members whose emotion
ecognition, and possibly expression, is impaired may  impact on the
ontrols’ expression and recognition of emotion, and they are more
ikely than unrelated volunteers to be subject to similar stresses,
nd therefore have similar levels of anxiety and depression. In
upport of this, gene-negative controls in some studies have been
hown to perform below “healthy” control level at facial emotion
ecognition (Gray et al., 1997; Henley et al., 2008; Sprengelmeyer
t al., 2006). Use of a gene-negative control group therefore aims
o minimise group differences attributable to social or emotional
actors.
.2.3. Stimulus type, presentation and response options
As mentioned above, the majority of studies used very simi-
ar stimulus sets. Facial stimuli were usually based on the Ekman
nd Friesen set (Ekman and Friesen, 1976). However there are a
umber of variations of this: whether simple faces or the Emotion
exagon are used, whether or not neutral faces are included, and
he overall number of stimuli used. Only two studies included non-
kman facial stimuli, one using a similar black and white static set
Snowden et al., 2008) and one making their own colour videos
rom actors (Montagne et al., 2006).
Similarly, studies of vocal emotion recognition tended to use
timuli drawn from the same set (either a set of non-verbal vocal
ounds, see Scott et al. (1997),  Calder et al. (2004),  or the prosodic
timuli used by Sprengelmeyer et al. (1996)). One exception was
ayes et al. (2007) where it seems that novel non-verbal vocal
timuli were used.
There were a number of subtle variations of presentation and
esponse options, particularly pertinent to facial stimuli as these
re not naturally time-limited (as auditory stimuli are). Some faces
ere presented for a limited time, others were presented until par-
icipants had made a choice. As mentioned above, in the Emotion
exagon test each stimulus is repeated six times (responses from
he ﬁrst presentation being discarded as practice items), whereas
n simple face tests each stimulus is presented only once.
Most studies did not impose a ﬁxed time to respond, but two
imited the time available in which a response could be made
Johnson et al., 2007; Tabrizi et al., 2009). All studies of facial and
ocal emotion recognition used an alternative forced choice (AFC)
esponse paradigm, but they varied in the choices given. Most gave
he same number of response options as there were emotion cat-
gories (e.g. if six different emotions were presented, there wouldck-HD team (personal communication).
ically start at the end of compulsory education (after 11 years of schooling in the
be six response options). One deliberately reduced the number
of responses (Snowden et al., 2008) in order to evaluate perfor-
mance when task demands were decreased. One study used a 6AFC
response when only four different emotions were represented in
the stimuli (Aviezer et al., 2009).
3.2.4. Statistical analysis
3.2.4.1. Power analysis and sample size. Only two studies reported
considerations of power and sample size calculation (Johnson et al.,
2007; Tabrizi et al., 2009). These were the two largest studies (over
100 participants in the patient groups), and both had calculated that
they were adequately powered to detect relatively small effects
in premanifest and manifest HD populations. Sample sizes in the
remaining studies ranged from six (Mitchell et al., 2005, odour test)
to 40 (Henley et al., 2008).
3.2.4.2. Potential confounding variables. Potential confounding
variables were dealt with in a number of different ways. Almost all
studies reported gender, age and some measure of estimated pre-
morbid intelligence or educational level. Most of these reported
that groups were “matched” for one or more of these variables, and
some, but not all, reported a statistic to conﬁrm that there were
no statistically signiﬁcant differences between groups. Four stud-
ies included some or all of these variables as covariates in their
analysis (Henley et al., 2008; Johnson et al., 2007; Milders et al.,
2003; Tabrizi et al., 2009).
Almost all studies that tested facial emotion recognition
included a standard test of face recognition2 and sometimes a test
of visual acuity or contrast sensitivity, and other visual or face
processing tasks (the exception was Tabrizi et al. (2009),  which
was designed to assess potential biomarkers, rather than to test
facial emotion recognition per se). One study excluded two partic-
ipants with poor acuity (Aviezer et al., 2009), and no other studies
reported impairments in basic visual skills. Six studies reported
that performance on the Benton Facial Recognition Test was signif-
icantly worse in HD groups than control groups. Two took this into
account in their analysis: one adjusted for facial recognition abil-
ity by including Benton score as a covariate in the analysis (Henley
et al., 2008) and one investigated whether Benton scores correlatedrecognition analysis although mean (SD) Benton data in most cases
2 Benton Facial Recognition Test (Benton et al., 1978).
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Table 2
Technical assessment.
Control type: = gene-negative/spouses; = gene negative unaware of status; = healthy volunteers.
Power analysis/sample size: = analysis performed; = no analysis performed.
Normality of data considered: = discussed, and stats adapted accordingly; = stats adjusted for
inhomogeneity of variance only; = not discussed.
Multiple comparisons addressed: = discussed and addressed; = not discussed.
Confounders measured and controlled for: = effect of potentially confounding variables taken into
y conf
s
e
w
t
t
I
taccount in analysis; = effect of some potentiall
= not considered.
uggest that some participants may  have been fallen into the “mod-
rately impaired” range. In two studies in which a group difference
as not found on the Benton, some HD participants still scored inhe “moderate impairment” or “severe impairment” range although
his is not commented on (Aviezer et al., 2009; Gray et al., 1997).
n addition to those studies that reported group differences in Ben-
on score, one study included Benton as a covariate in the mainounding variables taken into account in analysis;
analyses although did not report whether group differences were
statistically signiﬁcant (Johnson et al., 2007).
Studies that included auditory stimuli did not report testing
auditory perception. The one study that investigated taste and
olfactory recognition tested olfactory identiﬁcation and threshold
and excluded two HD participants from the olfactory experiment
on the basis of poor performance (Mitchell et al., 2005).
 Biobe
w
v
g
i
e
f
i
w
3
d
c
s
v
v
w
H
M
f
y
s
(
3
e
c
o
e
i
r
e
i
3
i
r
f
t
(
S
s
g
3
i
d
t
i
t
a
A
t
s
a
c
e
s
r
r
sS.M.D. Henley et al. / Neuroscience and
Overall, potential confounding variables were not always dealt
ith satisfactorily. Very few studies adjusted for demographic
ariables despite the fact that non-statistically signiﬁcant between-
roup differences in demographic variables can still materially
mpact on between-group differences in other variables (Johnson
t al., 2007). Additionally, in some cases it seems likely that poor
acial recognition skills in one or two HD participants may  have
mpacted on the emotion recognition scores for the group as a
hole.
.2.4.3. Normality of data. The majority of studies noted that data
id not meet assumptions needed for parametric statistics. Many
ited ceiling effects and used non-parametric tests (e.g. techniques
uch as Mann-Whitney tests, or using bootstrap conﬁdence inter-
als), whilst some just acknowledged heterogeneity of residual
ariance between groups and used appropriate statistics for this.
Five studies used parametric statistics and did not discuss
hether the data were normally distributed (Aviezer et al., 2009;
ayes et al., 2007; Milders et al., 2003; Mitchell et al., 2005;
ontagne et al., 2006). One study used non-parametric statistics
or behavioural data, but opted to use parametric statistics for anal-
sis of untransformed mean reaction time data, although it would
eem likely that such data might have been positively skewed
Sprengelmeyer et al., 2006).
.2.4.4. Multiple statistical comparisons. All studies reported sev-
ral statistical comparisons. Three studies reported Bonferroni-
orrected results (controlling the false positive rate across a number
f comparisons) (Calder et al., 2010; Hayes et al., 2007; Milders
t al., 2003). Three studies discussed the increased risk of false pos-
tives but preferred to maximise power by reporting uncorrected
esults (Henley et al., 2008; Snowden et al., 2008; Sprengelmeyer
t al., 2006). The remaining ten studies did not discuss this
ssue.
.2.4.5. Reporting of analysis and results. The majority of stud-
es reported their analysis and test results clearly. Most studies
eported two-tailed tests. Four studies chose to use one-tailed tests
or some or all of their comparisons based on a priori predictions
hat the HD group would, on average, do worse than controls
Gray et al., 1997; Hennenlotter et al., 2004; Kipps et al., 2007;
prengelmeyer et al., 2006) although Sprengelmeyer et al. (2006)
till report one test in which the HD group outperformed the control
roup.
.3. Outcomes
Outcomes are described separately for manifest and preman-
fest populations as this is how the majority of studies were
esigned. As discussed above, this is a somewhat arbitrary dis-
inction, based on an assessment of motor symptoms. There is
nevitably variation between clinicians with regard to when symp-
oms are judged sufﬁcient to make a diagnosis of manifest disease,
nd different studies use different cut-off points to deﬁne this.
viezer et al. (2009) included both manifest and premanifest par-
icipants in a single group in their study. Examination of their data
hows that nine out of 21 participants who completed the study had
 UHDRS motor score of ﬁve or less, a cut-off used elsewhere to dis-
riminate between manifest and premanifest participants (Tabrizi
t al., 2009). Therefore since the majority of participants had clear
igns of the disease, Aviezer et al.’s results are reported below as
epresenting manifest HD.
Outcomes are described as statistically signiﬁcant if they were
eported as such in the original study. The majority of studies
et p < 0.05 as the cut-off for statistical signiﬁcance. As reportedhavioral Reviews 36 (2012) 237–253 245
above, studies varied as to whether or not they adjusted this cut-
off for multiple comparisons. Therefore in studies that opted to
use a Bonferroni-type correction larger effect sizes will have been
required in order for a result to be reported as statistically signiﬁ-
cant, relative to studies that did not opt to use this correction.
3.3.1. Facial emotion recognition
In participants with manifest HD the most consistent evidence of
impairment was shown for recognition of facial anger: statistically
signiﬁcant effects were found in every study that included a test for
it. Evidence of disgust recognition impairment was also found in
almost every study that tested it. The only exception was  Snowden
et al. (2008) in a task in which they gave a two-alternative forced
choice response option to the Ekman faces, instead of the usual
six (i.e., they reduced task demands); anger and fear recognition
were still impaired in this condition. Evidence that fear recogni-
tion was  impaired was  often found, although only using Ekman
stimuli (not moving facial stimuli (Montagne et al., 2006), or a non-
Ekman stimulus set, the “Manchester” set, a different, locally-made
set of black-and-white static emotion faces (see Snowden et al.,
2008)). Sadness and surprise recognition were found to be impaired
less often, whilst a statistically signiﬁcant impairment in happi-
ness recognition was only found by two  groups (Calder et al., 2010;
Hayes et al., 2009) (Table 3).
In premanifest participants a statistically signiﬁcant impair-
ment in disgust recognition was  most frequently reported and
was seen in ﬁve out of eight studies. Three of these reported evi-
dence that disgust was  selectively impaired (Gray et al., 1997;
Hennenlotter et al., 2004; Sprengelmeyer et al., 2006), whilst two
found an impairment across negative emotions (Johnson et al.,
2007; Tabrizi et al., 2009). Sprengelmeyer et al. (2006) also reported
evidence of a deﬁcit in surprise recognition at the third of three
timepoints tested. The remaining three studies found no evidence
of impairment at all in premanifest participants, although one study
explained a ﬁnding of impaired happiness recognition as an arte-
fact of the ceiling effect in controls for that emotion (Henley et al.,
2008).
Snowden et al. (2008) found evidence that manifest HD partic-
ipants were impaired at recognising sadness and disgust from the
eye regions alone (Table 3).
3.3.2. Vocal emotion recognition
In manifest participants evidence of an impairment in vocal dis-
gust recognition was found consistently (four out of four studies)
for both short non-verbal vocal sounds and speech prosody. Anger
recognition was  found to be statistically signiﬁcantly impaired
in the three studies using non-verbal vocal sounds, but not for
prosody. Evidence of an impairment in fear recognition was also
found in three out of four studies, including both non-verbal vocal
sounds and prosody. Using prosodic stimuli, statistically signiﬁ-
cant impairments were also reported for recognising surprise and
happiness (Sprengelmeyer et al., 1996) although no other studies
reported evidence of deﬁcits in these emotions. No studies reported
statistically signiﬁcant impairments in recognising sadness from
vocal sounds (Table 4).
Only one study tested vocal emotion recognition in a premani-
fest cohort (Sprengelmeyer et al., 2006) and reported no evidence
of impairments at any of three timepoints tested, using a combined
score from sounds and prosodic stimuli (Table 4).
3.3.3. Recognition of emotion in other modalities
Aviezer et al. (2009) found no evidence that their HD popu-lation was  impaired at recognising sad, disgusted or angry body
language. Some of the body language stimuli contained semantic
clues (dirty underwear for disgust, and a gravestone for sadness). It
is possible that people with HD were able to label the images based
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Table  3
Facial emotion recognition results.
Population Study Stimuli Ha Sa Su Di An Fe Ne
Manifest HD Aviezer et al. (2009) Ekman faces © ©  
Calder et al. (2010) Ekman faces      
Emotion hexagon      
Hayes  et al. (2009) Emotion hexagon ©     
Ekman faces at different intensities ©    
Henley et al. (2008) Ekman faces © ©    
Milders et al. (2003) Ekman faces ©  ©   
Montagne et al. (2006) Videos at different intensities © © ©   
Snowden et al. (2008) Ekman faces (6AFC) ©     
Ekman faces (2AFC) © © © ©  
Manchester faces © © ©   © ©
Sprengelmeyer et al. (1996) Emotion hexagon ©     
Ekman faces ©     
Tabrizi et al. (2009) Ekman faces (©) () (©) () () () (©)
Manifest  HD Snowden et al. (2008) Manchester eyes ©  ©  © © ©
Premanifest HD Gray et al. (1997) Ekman faces © © ©  © ©
Henley  et al. (2008) Ekman faces  © © © © ©
Hennenlotter et al. (2004) Emotion hexagon © © ©  © ©
Johnson et al. (2007) Ekman faces ©  ©    ©
Kipps  et al. (2007) Emotion hexagon © © © © © ©
Milders et al. (2003) Ekman faces © © © © © ©
Sprengelmeyer et al. (2006)a Ekman faces + Emotion hexagon © © ()  © ©
Tabrizi et al. (2009)b Ekman faces (©) () (©) () () () (©)
Key: Ha = happiness; Sa = sadness; Su = surprise; Di = disgust; An = anger; Fe = fear; Ne = neutral.  = between-group difference; © = no between-group difference; blank = not
tested.
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b Composite “negative emotion” score tested.
n previously acquired semantic knowledge, rather than recogni-
ion of the emotion conveyed by the body postures of the models.
itchell et al. (2005) reported that their manifest HD cohort tended
o rate unpleasant odours and taste combinations as less disgusting
han controls, and that this difference was statistically signiﬁcant.
owever this study differed from those for the facial and vocal
odalities in using subjective ratings, rather than categorisation of
n objective stimulus; mean ratings suggest that participants with
D were still able to discriminate between pleasant and less pleas-
nt stimuli, which makes it hard to draw inferences about more
peciﬁc recognition impairments in this paradigm (Table 5).
.3.4. Cross-modal comparisons
Several studies included tests of emotion recognition in more
han one modality, although they only report independent statis-
ics for group differences in each modality (i.e., they do not directly
tatistically compare performance between modalities). Aviezer
t al. (2009) reported that anger and disgust recognition from
kman faces was statistically signiﬁcantly impaired in the absence
f impairments in recognising emotional body language. Calder et
l. (2010) found evidence of a global impairment in recognising the
ix canonical emotions from Ekman faces, but evidence that only
isgust, anger and fear recognition were impaired from non-verbal
able 4
ocal emotion recognition results.
Population Study Stimuli 
Manifest HD Calder et al. (2010) Non-verbal vocal sounds 
Hayes et al. (2007) Non-verbal vocal sounds 
Snowden et al. (2008) Non-verbal vocal sounds
Sprengelmeyer et al. (1996) Prosody 
Premanifest HD Sprengelmeyer et al. (2006) Prosody + non-verbal vocal 
ey: Ha = happiness; Sa = sadness; Su = surprise; Di = disgust; An = anger; Fe = fear; Ne = ne
ested.vocal sounds. A similar pattern was  shown by Snowden et al. (2008)
using the same face stimuli: recognition of all emotions except hap-
piness was  statistically signiﬁcantly impaired with facial stimuli,
whilst only disgust, anger and fear were impaired with non-verbal
vocal sounds. However using a different set of faces Snowden et al.
(2008) reported evidence of impairment only for disgust and anger
recognition. In the study of Sprengelmeyer et al. (1996) subjects
showed evidence of impaired recognition of surprise, disgust and
fear from both facial expressions and prosody, but impaired sadness
and anger recognition only from facial expressions. In a preman-
ifest cohort, evidence of a selective impairment recognising the
facial expression of disgust was found in the absence of impair-
ments for the other ﬁve canonical facial emotions, or any deﬁcits
in recognising emotions from sounds or prosody (Sprengelmeyer
et al., 2006).
3.3.5. Disproportionate deﬁcits in recognition of speciﬁc emotions
Early reports suggested that HD gene carriers (both manifest
and premanifest) were disproportionately impaired at recognis-
ing disgust, both using faces and prosody (Gray et al., 1997;
Sprengelmeyer et al., 1996). Sprengelmeyer et al. (1996) tested
this statistically, expressing manifest HD scores as a proportion
of the mean score in controls (to adjust for emotion difﬁculty)
Ha Sa Su Di An Fe Ne
© © ©   
©   ©
© © ©   
 ©   © 
sounds © © © © © ©
utral. = between-group difference; © = no between-group difference; blank = not
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Table  5
Emotion recognition in other modalities.
Population Study Stimuli Ha Sa Su Di An Fe Ne
Manifest HD Aviezer et al. (2009) Body language © © ©
Mitchell et al. (2005) Odours 
Tastes 
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ested.
nd comparing disgust recognition with the next worst recognised
motion, fear. Disgust recognition was statistically signiﬁcantly
orse than fear recognition for Ekman Faces, Emotion Hexagon,
nd prosodic stimuli; HD participants scored at or below chance
evel. Sprengelmeyer et al. (2006) also report that in a premanifest
ohort facial disgust recognition was the only emotion to be statis-
ically signiﬁcantly impaired relative to controls, and that 5/12 gene
arriers were only impaired (judged by z scores) at disgust, whilst
he other seven participants were either unimpaired, or globally
mpaired. Three other studies report selective or disproportion-
te impairments in disgust recognition. Gray et al. (1997) and
ennenlotter et al. (2004) both found evidence that facial disgust
ecognition was the only emotion impaired in premanifest cohorts,
lthough this was not assessed statistically in relation to other emo-
ions. Hayes et al. (2007) reported that more HD participants had z
cores of >−1.56 (and more scored at levels judged consistent with
hance) for non-verbal vocal disgust recognition than for any other
ocal emotion, although again, differences between emotions were
ot assessed statistically.
Most other studies do not report selective or disproportion-
te impairments in disgust recognition. Hayes et al. (2009) tested
ifferences between emotions and found no evidence that one
as more impaired than any other (Ekman Faces and Emotion
exagon). Henley et al. (2008) compared emotion recognition
erformance statistically (adjusting for control scores) and found
ecognition of anger to be disproportionately impaired (Ekman
aces). Milders et al. (2003) found evidence that recognition of dis-
ust was less impaired than recognition of anger, fear and sadness
Ekman Faces). Snowden et al. (2008) reported either no evidence
f impairment of disgust recognition (Ekman Faces with 2AFC), or
hat no patient got their worst scores at disgust recognition (Ekman
aces with 6AFC); when assessed statistically, disgust recognition
n their HD group was no worse (and in one case was better)
han fear and anger recognition both for the Manchester faces
nd eyes set (see Section 3.3.1), and for non-verbal vocal sounds.
ther studies did not test inter-emotion differences statistically but
rgued that the pattern of ﬁndings did not support a disproportion-
te impairment of disgust recognition (e.g., Aviezer et al., 2009;
alder et al., 2010, who found a greater number of HD participants
mpaired at anger across all tasks; Johnson et al., 2007; Montagne
t al., 2006).
.3.6. Within-modality stimulus type comparisons
Many studies used both the “Ekman Faces” set, as well as the
Emotion Hexagon”. Calder et al. (2010) reported similar deﬁcits
across all emotions except happiness) with both stimulus sets.
ayes et al. (2009) found evidence that sadness, surprise, disgust,
nger and fear recognition were impaired using both the Emotion
exagon, and Ekman Faces at varying intensities, although happi-
ess was only impaired on the Ekman Faces set, and no impairment
as seen for 25% and 50% sad Ekman Faces. Snowden et al.2008) compared the Ekman Faces set 6AFC, with 2AFC, an alter-
ative face set, and eye regions only. They reported a statistically
igniﬁcant recognition deﬁcit across all emotions except happi-
ess using Ekman Faces, reduced to anger and fear recognitionutral.  = between-group difference; © = no between-group difference; blank = not
deﬁcits when the task was  simpliﬁed (2AFC), whilst only disgust
and anger recognition were impaired on the alternative “Manch-
ester” set, and sadness and disgust recognition using eye regions
only.
3.3.7. Summary
Disgust, anger and fear recognition were most often impaired
in manifest HD populations, across modalities. For face recogni-
tion, the most frequently tested modality with the most consistency
in stimulus presentation, a deﬁcit in anger recognition was  found
in all the studies in which it was tested. In premanifest popu-
lations deﬁcits are more commonly seen for disgust recognition
than any other emotion, but only in the facial modality. Whilst dis-
gust recognition appears disproportionately impaired in some HD
populations, this is not true of all populations tested, nor across
modalities. Outcome varies depending on the type of stimulus used
(even within a modality).
4. Discussion
Certain general conclusions emerge from this review of stud-
ies of emotion recognition in HD. Considering ﬁrstly the most
widely used emotional stimulus (facial expressions), anger recog-
nition appears to be most consistently impaired in manifest HD
populations, closely followed by recognition of disgust and fear,
whereas recognition of sadness and surprise are less consistently
affected, and recognition of happiness only rarely affected. Indi-
viduals with pre-manifest HD may  exhibit no detectable deﬁcit;
however, if there is an impairment of emotion recognition this is
likely to affect disgust or recognition of negative facial emotions
more generally. Deﬁcits of facial emotion recognition become more
likely, more severe and more widespread with the conversion from
premanifest to manifest disease. However, the lack of uniformity in
measures of disease stage and severity across studies precludes a
precise statement about the time course or proﬁle of these deﬁcits;
this is one of the biggest weaknesses in the literature. HD is known
to be highly heterogeneous, and clearly this natural clinical variabil-
ity may  underlie many of the inter-study differences reported here,
meaning that where differences do exist, they are not necessarily
contradictory. Nevertheless, between-group differences in levels of
potential confounds (e.g. CAG repeat length, or severity) may  also
underlie differences in behavioural ﬁndings, and until these con-
founds are reported consistently this will be impossible to judge.
In line with early work in the ﬁeld, initial evidence suggested
that that impaired recognition of facial expressions of disgust
occurs early in HD (Gray et al., 1997; Hennenlotter et al., 2004;
Sprengelmeyer et al., 2006); however, two large studies have
suggested that this deﬁcit may  occur in the context of a more
widespread impairment affecting negative emotions, even early in
the course of premanifest stages of disease (Johnson et al., 2007;
Tabrizi et al., 2009). In manifest HD, most studies do not suggest a
disproportionate defect of a particular emotion when recognition of
different emotions is compared directly, though negative emotions
are generally affected more severely than the positive/ambiguous
emotions of happiness and surprise. Taken together the evidence
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[Spanish]. Revista Neurologica
Argentina, 32, 20-34.
Arango-Lasprilla, J. C., Rogers, H.,
Lengenfelder, J., Deluca, J.,
No emotion recognition tasks in
battery.48 S.M.D. Henley et al. / Neuroscience and
uggests that recognition of various negative emotions may  be
ffected from an early stage in HD, and that impairments worsen
cross emotions as disease evolves.
Information about recognition of emotions via other sensory
hannels in HD remains too limited for ﬁrm conclusions to be
rawn. However, at least for vocal emotion recognition, the picture
merging is broadly convergent with the data for facial expressions.
n studies of manifest HD recognition of vocal disgust is consistently
mpaired, although recognition of vocal anger and fear are often
lso impaired. Evidence concerning the relative degree of impair-
ent for particular vocal emotions is conﬂicting (Calder et al., 2010;
ayes et al., 2007; Snowden et al., 2008; Sprengelmeyer et al.,
996). The few data available for premanifest HD have not provided
vidence of an early deﬁcit of vocal emotion recognition. This pat-
ern suggests that, as for facial expression, impaired recognition
f vocal expressions in HD may  become more salient with evolv-
ng disease and may  be more marked for negative than for positive
motions. It is likely that there are modality-speciﬁc factors here:
or example, the apparent preservation of recognition of vocal (in
ontrast to facial) expressions of sadness may  mean that sadness
s intrinsically easier to recognise from auditory than from visual
ues (Rohrer et al., 2010) or that different sensory modalities are
ifferentially affected in HD. However, inter-modality differences
ave yet to be evaluated statistically.
These ﬁndings have important clinical implications. One key
mplication is that emotion recognition could potentially serve
s a biomarker of disease onset and progression in HD. Emo-
ion scores (both composites and individual emotions) are already
ncluded in the two largest ongoing longitudinal studies, PREDICT-
D (Paulsen et al., 2006) and Track-HD (Tabrizi et al., 2009) and
urther work should demonstrate how sensitive emotion recog-
ition is at tracking decline over time, relative to other potential
arkers.
From the perspective of the individual patient with HD, these
esults clearly show that manifest HD is associated with impaired
ecognition of negative emotions. Furthermore, subtle impair-
ents of emotion processing can be detected many years before
otor onset. There is little formal evidence concerning the impact
f emotional deﬁcits on the social functioning of people with HD.
owever, the results of this analysis suggest the potential for some
ompensation if multiple (especially non-facial) channels can be
sed to convey emotional information to people with HD.
There are important limitations on an analysis of this kind. The
eview was limited to peer-reviewed publications: an important
otential source of bias in attempting to estimate the overall sig-
iﬁcance of emotion recognition deﬁcits in HD. In addition, the size
nd comprehensiveness of the studies included in the review var-
ed widely. Small studies are potentially under-powered to detect
mall effects or to adjust for confounding factors (particularly for
on-standard data distributions), whilst in large studies it may  be
ore difﬁcult to tailor assessments to particular kinds of deﬁcits
r to assess deﬁcits comprehensively. A further source of variation
etween studies is linked to the different paradigms used to assess
motion recognition, even within a modality (e.g., facial expres-
ions); using different stimulus sets does lead to divergent ﬁndings
Snowden et al., 2008) and our understanding of emotion pro-
essing mechanisms remains too rudimentary to offer a principled
ccount of this.
This review suggests certain clear directions for further work.
here is a need for large, longitudinal studies of emotion compre-
ension in HD that are informed by emerging neurobiological data
nd which use consistent measures of disease stage and overall
everity as well as uniform assessment instruments. In future stud-
es it will be important to compare emotion processing in different
ensory modalities statistically, and at different levels of response
autonomic as well as cognitive); and to extend the assessmenthavioral Reviews 36 (2012) 237–253
to include more ecological kinds of emotion processing beyond
the relatively artiﬁcial scenario of the forced-choice recognition
protocol. There is also a need to understand how these deﬁcits,
and the other cognitive difﬁculties noted in this disease, impact
on patients’ everyday lives. The data that are currently available
suggest that there is no ‘magic bullet’ of selective emotional impair-
ment that is speciﬁc or selective for HD. On the other hand, the
data provide grounds for some optimism that emotion compre-
hension is a useful paradigm of disease onset and progression
in HD. Like other diseases, HD will almost certainly beneﬁt from
the exciting progress currently being made in the basic neuro-
science of human emotion. However, the study of patients with HD
could also inform this enterprise, and the structural and functional
anatomical bases for altered emotion processing in HD should be
addressed in hypothesis-led studies motivated by the neuropsy-
chological data. As neuropsychological metrics of clear relevance
to patients’ everyday lives, there is an overarching need further to
evaluate emotion processing measures as potential biomarkers for
symptomatic and disease-modifying therapies in this devastating
disease.
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Wilson’s disease. Neuropsychologia,
41, 527-537.
Genetic conﬁrmation not available
(Wang, personal communication).
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battery.
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event-related potentials in
Huntington’s disease.
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Wetter, S. R. (2003). Olfactory
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67-73.
Commentary.
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van Vugt, J. P., Lanser, J. B., Hermans,
J.,  Zwinderman, A. H. et al. (2003).
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[References]. Trends in Cognitive
Sciences, Vol.1, 322-325.
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Journal of Neurology, Neurosurgery
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testing.
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Study and reference Reason for exclusion
Aviezer et al.  (2009): Experiment 2 Participants were asked to
identify facial emotion
expressions that were
superimposed on body
images portraying a different
emotion and thus the
experiment was not
assessing “pure” emotion
recognition in either
modality.
Calder et al. (2010): Study 2 Participants were asked to
match photographs of
different “types” of disgust
recognition with a written
scenario, i.e., was too speciﬁc
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Hayes et al. (2007): Experiments 1, 3, 4, 5, 6, 7 These experiments did not
include an overt recognition
component. Expt. 1 required
participants to describe
situations that would induce
emotions, in Expt. 3
participants had to
categorise emotional words,
in Expt. 4 they had to
categorise emotion-inducing
scenes, all of which might
rely solely or in part on
semantic knowledge. In Expt.
5 their experience of disgust
was assessed using a
questionnaire, and in Expts. 6
and 7 they were asked to rate
odours and tastes but this did
not include the explicit label
“disgust”.
Milders et al. (2003): Test 2 Test 2 involved matching
facial expressions and
therefore did not meet
criteria for explicit emotion
recognition.
Snowden et al. (2008): Tasks 1, 2, 3, 6, 7 Task 1 required participants
to deﬁne emotion labels,
Task 2 asked participants to
pick synonyms or link
emotion words with speciﬁc
scenarios, and Task 3
repeated Task 2 but with
reduced response options;
thus these tasks were not
examining explicition
recognition of emotional
stimuli. Task 6 was a facial
expression matching task,
and Task 7 assessed facial
identity matching.
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